Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–2 of 2 stories
The FDA issued a complete response letter to REGENXBIO for its gene therapy RGX-121, intended for mucopolysaccharidosis type 2 (MPS II), also known as Hunter syndrome. The agency raised concerns regarding clinical trial eligibility criteria and its ability to differentiate between disease types.
Read full storyRegenxbio's RGX-202 gene therapy for Duchenne muscular dystrophy (DMD) demonstrated significant improvements in patient outcomes, exceeding expected disease progression at 12 and 18 months post-treatment in a pivotal trial. The company plans to submit a Biologics License Application (BLA) in mid-2026 via an accelerated approval pathway.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.